Ajovy vs. Emgality

Emgality (fremanezumab-vfrm) and Emgality (galcanezumab-gnlm) are calcitonin gene-related peptide antagonists indicated for the preventive treatment of migraine in adults.

Side effects of Emgality and Emgality that are similar include injection site reactions (pain, swelling, itching, and redness).

Both Emgality and Emgality may interact with other drugs.

Common side effects of Ajovy include:

• injection site reactions (pain, swelling, and redness)

Common side effects of Emgality include:

• injection site reactions such as pain, redness, and itching

Ajovy (fremanezumab-vfrm) is a calcitonin gene-related peptide antagonist indicated for the preventive treatment of migraine in adults.

Emgality (galcanezumab-gnlm) is a calcitonin-gene related peptide antagonist indicated for the preventive treatment of migraine in adults.

Ajovy may interact with other drugs. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant or plan to become pregnant before using Ajovy; it is unknown how it would affect a fetus. It is unknown if Ajovy passes into breast milk. Consult your doctor before breastfeeding.

Emgality may interact with other drugs. Tell your doctor all medications and supplements you use.

Two subcutaneous dosing options of Ajovy are available to administer the recommended dosage: 225 mg monthly, or 675 mg every 3 months (quarterly). The 675 mg quarterly dosage is administered as three consecutive injections of 225 mg each.

The recommended dosage of Emgality is a 240 mg loading dose (administered as two consecutive injections of 120 mg each), followed by monthly doses of 120 mg.